MYBL2 maintains stemness and promotes theta-mediated end joining in triple negative breast cancer
Rachel Bayley, Anna Munsey, Suman Ahmed…·Paloma García
This study shows MYBL2 maintains stemness and promotes theta-mediated end joining in TNBC, and identifies Pol{theta}/ATR inhibition as a therapeutic strategy.